DIFFERENCES IN 24-H AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN PATIENTS SWITCHED BETWEEN DIFFERING EXTENDED-RELEASE FORMULATIONS OF NIFEDIPINE: DOSE SCALING BETWEEN 30-MG VS. 60-MG DOSES

摘要

BACKGROUND: Pharmacies frequently switch patients between the two once-daily osmotic pump formulations of nifedipine-extended-release (nifedipine-XL) deemed to be bioequivalent in Canada. We recently demonstrated statistically significant and clinically important differences in 24-h systolic blood pressures (SBP) when patients are switched between the two 60-mg versions of nifedipine-XL (the original two-compartment pump sold under the brand name Adalat XL = AdN and the newer one-compartment pump sold as Mylan-nifed-ipine-XL = MyN). We report the comparison of SBP results from ABPM studies on patients switched between the two 30-mg versions of nifedipine-XL (AdN and MyN), and contrast with the 60-mg results using the same protocol.